These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 7665232

  • 1. Sequence-dependent antitumor activity of paclitaxel (taxol) and cisplatin in vivo.
    Milross CG, Peters LJ, Hunter NR, Mason KA, Milas L.
    Int J Cancer; 1995 Sep 04; 62(5):599-604. PubMed ID: 7665232
    [Abstract] [Full Text] [Related]

  • 2. Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
    Fujimoto S, Chikazawa H.
    Jpn J Cancer Res; 1998 Dec 04; 89(12):1343-51. PubMed ID: 10081496
    [Abstract] [Full Text] [Related]

  • 3. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel.
    Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L.
    J Natl Cancer Inst; 1996 Sep 18; 88(18):1308-14. PubMed ID: 8797771
    [Abstract] [Full Text] [Related]

  • 4. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
    Yamamoto K, Kikuchi Y, Kudoh K, Hirata J, Kita T, Nagata I.
    Jpn J Clin Oncol; 2000 Oct 18; 30(10):446-9. PubMed ID: 11185891
    [Abstract] [Full Text] [Related]

  • 5. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL, Watson JM, Gehrig PA, Fowler WC, Haskill JS.
    Cancer Res; 1999 May 15; 59(10):2425-32. PubMed ID: 10344753
    [Abstract] [Full Text] [Related]

  • 6. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol.
    Milas L, Hunter NR, Kurdoglu B, Mason KA, Meyn RE, Stephens LC, Peters LJ.
    Cancer Chemother Pharmacol; 1995 May 15; 35(4):297-303. PubMed ID: 7828272
    [Abstract] [Full Text] [Related]

  • 7. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM, Thakur B, Sakpal A, Singh RK, Ray P.
    Int J Biochem Cell Biol; 2015 Apr 15; 61():90-102. PubMed ID: 25681684
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
    Untch M, Sevin BU, Perras JP, Angioli R, Untch A, Hightower RD, Koechli O, Averette HE.
    Gynecol Oncol; 1994 Apr 15; 53(1):44-9. PubMed ID: 7909786
    [Abstract] [Full Text] [Related]

  • 9. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    Kawano M, Mabuchi S, Kishimoto T, Hisamatsu T, Matsumoto Y, Sasano T, Takahashi R, Sawada K, Takahashi K, Takahashi T, Hamasaki T, Kimura T.
    Int J Gynecol Cancer; 2014 Jun 15; 24(5):829-37. PubMed ID: 24844217
    [Abstract] [Full Text] [Related]

  • 10. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
    Goldberg JM, Piver MS, Hempling RE, Recio FO.
    Gynecol Oncol; 1996 Dec 15; 63(3):312-7. PubMed ID: 8946864
    [Abstract] [Full Text] [Related]

  • 11. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M.
    Semin Oncol; 1996 Oct 15; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [Abstract] [Full Text] [Related]

  • 12. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda A, Benito D.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [Abstract] [Full Text] [Related]

  • 13. Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-alpha.
    Seong J, Milross CG, Hunter NR, Shin HC, Milas L.
    Anticancer Drugs; 1997 Jan 15; 8(1):80-7. PubMed ID: 9147616
    [Abstract] [Full Text] [Related]

  • 14. Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
    Klaassen U, Harstrick A, Schleucher N, Vanhoefer U, Schröder J, Wilke H, Seeber S.
    Br J Cancer; 1996 Jul 15; 74(2):224-8. PubMed ID: 8688325
    [Abstract] [Full Text] [Related]

  • 15. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
    Takahashi R, Mabuchi S, Kawano M, Sasano T, Matsumoto Y, Kuroda H, Kozasa K, Hashimoto K, Sawada K, Kimura T.
    PLoS One; 2016 Jul 15; 11(3):e0151050. PubMed ID: 26986199
    [Abstract] [Full Text] [Related]

  • 16. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
    Kondo N, Tsukuda M, Kimura M, Fujita K, Sakakibara A, Takahashi H, Ishiguro Y, Toth G, Matsuda H.
    Oncol Rep; 2010 Feb 15; 23(2):355-63. PubMed ID: 20043095
    [Abstract] [Full Text] [Related]

  • 17. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.
    Winterhoff B, Freyer L, Hammond E, Giri S, Mondal S, Roy D, Teoman A, Mullany SA, Hoffmann R, von Bismarck A, Chien J, Block MS, Millward M, Bampton D, Dredge K, Shridhar V.
    Eur J Cancer; 2015 May 15; 51(7):879-892. PubMed ID: 25754234
    [Abstract] [Full Text] [Related]

  • 18. Effects of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenografts.
    Li W, Wan L, Zhai LY, Wang J.
    Int J Mol Sci; 2014 Oct 23; 15(10):19265-80. PubMed ID: 25342321
    [Abstract] [Full Text] [Related]

  • 19. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
    Yamazaki S, Sekine I, Saijo N.
    Gan To Kagaku Ryoho; 1998 Mar 23; 25(4):605-15. PubMed ID: 9530372
    [Abstract] [Full Text] [Related]

  • 20. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U, Schleucher N, Klaassen U, Seeber S, Harstrick A.
    Semin Oncol; 2000 Feb 23; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.